InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.670 0.025 (3.88%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$183 OCC Reports First Product Use and Sales of Celgro in Italy 17 Jul 2018 9:33AM $0.300 $0.670 risen by 123.33%
$183 Orthocell Appoints Exclusive Distributor in the UK 10 Jul 2018 8:55AM $0.310 $0.670 risen by 116.13%
$183 New CelGro Arthroscopic Tendon Regeneration Study Commences 2 Jul 2018 8:24AM n/a $0.670 n/a
$183 Dr. Jonathan Bell Appointed to Orthocell Advisory Board 25 Jun 2018 9:43AM $0.345 $0.670 risen by 94.20%
$183 Orthocell Announces Successful Ortho-ATI Study Results 14 Jun 2018 9:31AM $0.350 $0.670 risen by 91.43%
$183 Orthocell Announces Successful Tendon Study Results 6 Jun 2018 9:54AM $0.350 $0.670 risen by 91.43%
$183 First Product Use and Sales of CelGro in Poland 31 May 2018 9:30AM $0.355 $0.670 risen by 88.73%
$183 Orthocell Secures CelGro Patent Protection in Europe 24 May 2018 10:15AM $0.355 $0.670 risen by 88.73%
$183 First Product Use and Sale of CelGro in Europe 22 May 2018 9:36AM $0.355 $0.670 risen by 88.73%
$183 10th Patient Treatment Milestone in Human Tendon Study 17 May 2018 9:56AM $0.350 $0.670 risen by 91.43%
$183 Change of Director's Interest Notice * 5 11 May 2018 6:12PM $0.345 $0.670 risen by 94.20%
$183 Appendix 3B and Notice Under Section 708A 10 May 2018 11:10AM $0.345 $0.670 risen by 94.20%
$183 Orthocell Extends Distributor Network in the EU 8 May 2018 9:14AM $0.345 $0.670 risen by 94.20%
$183 Results of Meeting 7 May 2018 5:16PM $0.345 $0.670 risen by 94.20%
$183 Orthocell Announces Successful Bone Repair Study Results 1 May 2018 9:10AM $0.315 $0.670 risen by 112.70%
$183 Appendix 4C - quarterly 30 Apr 2018 6:14PM $0.315 $0.670 risen by 112.70%
$183 Orthocell Appoints First Distributor in the EU 30 Apr 2018 8:25AM $0.305 $0.670 risen by 119.67%
$183 Updated Investor Presentation 16 Apr 2018 8:25AM $0.300 $0.670 risen by 123.33%
$183 Investor Update 9 Apr 2018 6:45PM $0.305 $0.670 risen by 119.67%
$183 Notice of General Meeting/Proxy Form 6 Apr 2018 4:19PM $0.295 $0.670 risen by 127.12%
$183 Cedrus Investments Initiation of Coverage 4 Apr 2018 1:41PM $0.290 $0.670 risen by 131.03%
$183 Prof. Giuseppe Luongo Appointed to Orthocell Advisory Board 26 Mar 2018 8:26AM $0.315 $0.670 risen by 112.70%
$183 NDF Research Initiation of Coverage 20 Mar 2018 8:20AM $0.290 $0.670 risen by 131.03%
$183 Prof. Massimo Simion Appointed to Orthocell Advisory Board 19 Mar 2018 8:21AM $0.290 $0.670 risen by 131.03%
$183 FDA Publication Supports Regenerative Medicine Acceleration 15 Mar 2018 9:49AM $0.290 $0.670 risen by 131.03%

576 - 600 of 772 results

Page 24 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.